Introduction
HIV-1 protease is a widely exploited target for the development of antiviral agents against HIV-1 and several potent protease inhibitors are widely used in highly active antiretroviral therapy. 1 However, when full viral inhibition is not achieved, new drug-resistant variants emerge with the accumulation of mutations in the protease coding region, causing treatment to fail. 2 Therefore, the monitoring of drug resistance in HIV-1-infected patients is necessary for the design of salvage antiretroviral regimens. However, the diversity of HIV-1 and the complexity of drug regimens hinder the accurate assessment of drug resistance based solely on the genetic sequence, because of the existence of synergistic and antagonistic effects between drug resistance mutations. 3 As a result, genotypic prediction from complex mutational patterns may be inaccurate and only provide indirect evidence of drug resistance. Therefore, the development of phenotyping methods to complement the information obtained from genotyping has become essential.
Current phenotypic assays make use of a wide range of biological assays. The most common methods utilize HIV-1 isolates 4 or recombinant viruses 5 and some of them are commercially available. 6, 7 However, phenotyping has three basic limitations: the high biological risk; the complexity of the molecular basis; and the high cost. Lindsten et al. 8 and Majerova-Uhlikova et al. 9 reported a new protease assay in eukaryotic cells based on the expression of an HIV-1 protease fused to the green fluorescent protein (GFP). The fusion protein (GFP -PR) is activated in vivo by the autocatalytic cleavage of HIV-1 protease, resulting in the rapid elimination of protease-expressing cells, due to the cytotoxic effect of the protease. Treatment with protease inhibitors results in a dose-dependent accumulation of the fluorescent precursor, which can be detected and quantified.
In the present study, we took this assay beyond its original description. We modified the cloning vector to facilitate the introduction of HIV-1 protease from viral isolates of infected subjects and improved the detection method of the GFP reporter gene. We also propose a new molecular approach to phenotyping, namely, a non-infectious eukaryotic phenotypic system based on the ability of HIV-1 protease to cleave cellular translation factors, such as the eukaryotic translation initiation factor 4 (eIF4GI) and the poly(A)-binding protein (PABP). This capacity of HIV-1 protease leads to cyclical accumulation of GFP, depending on the dose of the protease inhibitor. Comparisons between values obtained using our assay and those described for other standardized methods of phenotyping viral proteases from 46 clinical isolates were performed to validate the technique. The method can be used for both the phenotyping of viral isolates resistant to protease inhibitors and the screening of new protease inhibitors.
Methods

Subject characteristics
The study was approved by the 'Germans Trias i Pujol Hospital' Ethics Committee and informed consent was obtained in writing from the study participants. Forty-six plasma samples from HIV-1 B subtypeinfected patients were analysed to validate our assay. Thirty-three patients had started a darunavir-containing salvage regimen and 13 patients had started a tipranavir-containing regimen. The samples were taken after treatment failure and before the initiation of new regimens. The subjects' characteristics are summarized in Table S1 (available as Supplementary data at JAC Online).
In addition, the molecular mechanism of the new assay was confirmed using four different HIV-1 protease-recombinant plasmids: pcDNA3_GFP_PR-wt (containing the wild-type protease of HIV-1 NL4-3 ); pcDNA3_GFP_PR-R I (containing a protease with the resistance mutations V32I, M46I, I47V, L90M, L10I and G73T, which confer intermediate resistance to protease inhibitors); pcDNA3_GFP_PR-R H (containing a protease with the resistance mutations I47V, G48M, I54A, V82T, L90M, L10V, L33F, A71V and T74P, which confer high-level resistance to protease inhibitors); and pcDNA3_GFP_PR-D25N (containing an inactive protease). The inactive HIV-1 protease D25N was kindly provided by M. A. Martinez (IrsiCaixa, Badalona, Spain).
Generation of HIV-1 protease-recombinant vectors
The protease-deleted vector pcDNA3_GFPDPR was constructed to facilitate the cloning of PCR-amplified fragments of HIV-1 protease from infected subjects. The plasmid pcDNA3_GFP_PR (containing a fusion protein GFP-wild-type HIV-1 protease) was obtained from K. Lindsten and N. P. Dantuma (Karolinska Institutet, Stockholm, Sweden). To construct the deleted plasmid (pcDNA3_GFPDPR), the protease of the plasmid pcDNA3_GFP_PR was deleted using the restriction enzymes BsrGI and EcoRV, and a polylinker was introduced. HIV-1 protease-recombinant vectors were generated by amplification and cloning of the HIV-1 protease from plasma samples. Briefly, RT 
Protease inhibitor phenotypic susceptibility assay
A total of 3×10 5 293T cells were transfected with 1.5 mg of pcDNA3_GFP_PR carrying the HIV-1 protease from selected subjects (Table S1 ) using the CalPhos TM Mammalian Transfection Kit (BD Biosciences) in 24-well plates. Eight dilutions ranging from 1.5 to 1000 nM tipranavir or from 1.5 to 100 nM darunavir were added in quadruplicate to each well. Twenty-four hours post-transfection, cells were stained with propidium iodide (BD Biosciences) and the expression of the GFP reporter gene was monitored by flow cytometry of propidium iodidenegative cells. Two different GFP-positive populations were clearly differentiated with high and low intensities, and only cell populations with high intensities of GFP were used to calculate the phenotypic susceptibility. The percentage inhibition was plotted against the drug concentration by calculating the difference between the geometric means of test wells and negative wells (without drug). The result was divided by the difference in the geometric mean between the positive control wells (at maximum drug concentration) and negative wells (without drug). Inhibition curves were defined using a sigmoid dose-response curve with a variable slope (GraphPad Prism v5.0 software). The fold change (FC) in drug susceptibility was determined by dividing the IC 50 for every protease-recombinant plasmid sample by the IC 50 for the tipranavir-or darunavir-sensitive protease-recombinant plasmid (pcDNA3_GFP_PR-wt).
Correlations between the non-infectious phenotypic assay and standardized genotyping and phenotyping methods
We assessed the concordance between the results expressed as FC drug susceptibility provided by our method (evaluating the 46 plasma samples) and the FC generated using alternative phenotyping methods. We used two methods based on a biological data-driven system for predicting HIV-1 drug susceptibility from a viral genotype (the Virco w TYPE HIV-1 test and the Stanford HIVdb) and a third method based on an in vitro phenotypic resistance assay that measures the level of resistance of recombinant HIV-1 from plasma samples (Antivirogram w ). The two drugs evaluated were tipranavir and darunavir, as these were the agents administered in the patients' new regimen. Correlation
Assay to measure HIV-1 susceptibility to protease inhibitors 33 JAC coefficients (Spearman's r) and the P value (two-tailed) were calculated using GraphPad Prism v5.0 software.
Cell viability assay
In order to evaluate the toxicity of HIV-1 protease-recombinant vectors in our system, 1.5 mg of pcDNA3_GFP_PR-wt was used to transfect 3×10 5 293T cells at saquinavir concentrations ranging from 0 to 2 mM. In addition, an empty protease-recombinant vector was used as a negative control. Forty-eight hours post-transfection, cells were stained with annexin V (a marker of apoptosis) and 7-amino actinomycin D (7-AAD, an indicator of cellular necrosis). Staining was carried out according to general annexin V and 7-AAD staining procedures (BD Biosciences). The percentages of cells positive for annexin V and 7-AAD were determined by flow cytometry for GFP-positive cells.
Real-time quantitative RT-PCR analysis of GFP
Transcription of the GFP-PR was quantified at 0 and 2 mM saquinavir. pcDNA3_GFP_PR-wt, pcDNA3_GFP_PR-R I , pcDNA3_GFP_PR-R H and pcDNA3_GFP_PR-D25N were used for this evaluation. A total of 3×10 5 293T cells were transfected with 1.5 mg of plasmids and the total RNA was isolated (RNeasy Mini Kit, Qiagen) 24 h post-transfection. In total, 1 mg of RNA was reverse transcribed to cDNA using TaqMan Reverse Transcription Reagents (Applied Biosystems). Real-time quantitative RT-PCR analysis of GFP was performed using the primers 5 ′ -CTG CTG CCC GAC AAC CA-3 ′ and 5 ′ -TGT GAT CGA GCA TCT CGT T-3 ′ , and the probe FAM 5 ′ -TGA GCA CCC AGT CCG CCC TGA-3 ′ TAMRA. The mRNA expression of GFP was relatively quantified using the endogenous gene GUSB (Applied Biosystems). Relative quantification is expressed as the ratio between the threshold cycle (Ct) values of GFP versus GUSB and normalized to the GFP expression of the positive control (pcDNA3_GFP_PR-wt at maximum drug concentration).
Western blot analysis of GFP, HIV-1 protease, eIF4GI and PABP proteins A total of 3×10 5 293T cells were transfected with 1.5 mg of the four protease-recombinant plasmids at 0, 0.6 and 2 mM tipranavir. Twentyfour hours post-transfection, GFP-positive cells were sorted, harvested and lysed. Protein quantification was performed using the bicinchoninic acid assay (Pierce). Protein samples were run using 4%-12% polyacrylamide electrophoresis gels (Invitrogen) and blotted onto nitrocellulose membranes using the iBlot TM Dry Blotting System (Invitrogen). After blocking, membranes were incubated overnight with rabbit polyclonal antibodies against eIF4GI and PABP or monoclonal antibodies against GFP, HIV-1 protease, actin and REF-1. After washing, membranes were incubated with antirabbit or antimouse goat antibodies labelled with horseradish peroxidase for 50 min and then revealed with ECL-Plus solution (Amersham Biosciences).
Statistical analysis
To assess the association between our phenotypic system and the number of mutations or alternative phenotyping methods, the t-test and Spearman's r coefficient were computed. The P values reported are two-tailed. GraphPad Prism v5.0 software was used for the analysis.
Results
HIV-1 protease does not induce cell death
Inducible expression of HIV-1 protease has been reported to cause mammalian cell death by a process compatible with necrosis and apoptosis. 10, 11 A possible mechanism proposed to explain how HIV-1 protease could decrease GFP expression, after the transfection of plasmids containing the GFP-PR, was through cell death induced by HIV-1 protease. 8, 9 In order to ascertain the molecular mechanisms involved in phenotyping, cell viability assays were performed with annexin V (apoptotic marker) and 7-AAD (necrotic marker). 293T cells were transfected with pcDNA3_GFP_PR-wt at saquinavir concentrations ranging from 0 to 2 mM. The results show that the percentages of annexin V-positive cells in all cases (including negative controls) were equal, independent of the drug concentration (Figure 1a) . The same results were observed after staining with 7-AAD (Figure 1a) . Consequently, the loss of GFP signal when the protease is fully acting on the system (in the absence of drug) is not due to cell death.
HIV-1 protease does not affect the cellular transcription machinery
To assess whether HIV-1 protease affected the cellular transcription, we used real-time quantitative RT-PCR of GFP in cells transfected with the vectors pcDNA3_GFP_PR-wt, -R I and -R H at 0 and 2 mM tipranavir. The results show that the amount of GFP mRNA was equal in all cases, regardless of the protease-recombinant plasmid and drug concentration used (Figure 1b) . Consequently, transcription of the GFP reporter gene was independent of the protease resistance mutations in the plasmids and the drug concentration used, suggesting that the molecular mechanisms of our phenotyping method are independent of the cellular transcription machinery.
HIV-1 protease alters cellular protein translation
To test the ability of HIV-1 protease to inhibit the translation of cellular proteins, 12 western blot assays were performed on 293T cells transfected with the vectors pcDNA3_GFP_PR-wt, -R I , -R H and -D25N at different tipranavir concentrations. The results for GFP detection showed that the whole GFP -PR was only visible when the drug inhibited HIV-1 protease and that this inhibition was dose-dependent ( Figure 1c ). In addition, the detection of GFP -PR was dependent on the resistance mutations contained within the protease, as shown in the vector containing PR-R H , which cannot be inhibited by the drug at any concentration. In contrast, cells transfected with inactive protease (D25N) showed detectable GFP -PR, even in the absence of the drug (Figure 1c ). This is due to the inability of this protease to excise itself from the fusion protein. The result for protease detection alone showed that visible protease, such as GFP-PR, was dependent on the drug concentration, protease resistance mutations and processing of the protease evaluated (Figure 1c ). In addition, evaluation of the cellular translation factors eIF4GI and PABP showed proteolytic processing when the HIV-1 protease was not inhibited. In contrast, evaluation of the inactive PR-D25N showed its inability to cleave eIF4GI and PABP (Figure 1d) . Those results show that the pattern of resistance mutations within the HIV-1 protease and the concentration of the protease inhibitor are able to modulate the translation of cellular proteins, suggesting that our phenotypic system is based on the ability of HIV-1 protease to cleave cellular translation factors.
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Protease inhibitor phenotypic susceptibility assay
A schematic representation of the phenotypic susceptibility assay is shown in Figure S1 (available as Supplementary data at JAC Online). Briefly, we improved the detection method of the GFP reporter gene by using the molecular mechanism described. After transfection of a plasmid encoding the fusion protein GFP -PR, two different GFP-positive populations were clearly differentiated with high and low GFP intensities. Only cell populations with high intensities of GFP were used to calculate the phenotypic susceptibility of each plasma-derived protease-recombinant vector. The validation of the phenotypic assay was performed with 46 plasma samples from HIV-1-infected subjects. Thirtythree and 13 samples were used to determine phenotypic susceptibility to darunavir and tipranavir, respectively, from patients starting salvage regimens containing those protease inhibitors. Results for FC drug susceptibility to each protease inhibitor and the pattern of resistance mutations for each sample are shown in Table 1 . When samples were stratified by the number of resistance mutations, the statistical analysis showed that there was a significant increase in FC drug susceptibility between samples containing 0 and 1 resistance mutations (P¼ 0.018), between samples containing 1 and 2 resistance mutations (P ¼ 0.032), and between samples containing 1 and ≥3 resistance mutations (P¼ 0.013) (unpaired t-test) (Figure 2a) . Overall, there was a correlation between the number of resistance mutations and FC drug susceptibility (P,0.0001, Spearman's r¼ 0.57) (Figure 2b ). These results show that the phenotypic assay is consistent with the genotype of the samples.
Correlation between non-infectious phenotyping and standardized genotyping and phenotyping methods
We performed several correlations to validate our phenotyping method. We assessed concordance between our results expressed as the FC provided and the FC generated using alternative phenotypic methods, namely the Virco w TYPE HIV-1 test and the in vitro Antivirogram w assay for both drugs. Significant correlations were observed between the Virco w TYPE HIV-1 Assay to measure HIV-1 susceptibility to protease inhibitors 35 JAC test and our phenotyping method (P,0.0001, Spearman's r¼ 0.60) (Figure 2c ). There was also a significant correlation between the Antivirogram w and our phenotyping method (P ¼ 0.0001, Spearman's r¼ 0.60) (Figure 2d) . Finally, when the phenotypic score interpreted with the Stanford HIVdb v6.0.8 algorithm was compared with that obtained using our FC, a significant correlation was observed between both parameters (P,0.0001, Spearman's r¼ 0.69) (Figure 2e ). These results show that the phenotypic method described is reliable and comparable to currently used methods based on genotyping data and susceptibility assays, thus confirming the predictive potential of the non-infectious cell-based method.
Discussion
The development of rapid, easy and safe non-infectious HIV-1 phenotyping methods is crucial for the management of subjects harbouring drug resistance mutations. Such methods have been reported previously. 13 -18 However, ideally, phenotypic systems would mimic physiological conditions; therefore, eukaryotic cells have been applied to develop new phenotypic systems using reporter genes. 8, 9, 19 Lindsten et al. 8 and Majerova-Uhlikova et al. 9 reported a new protease assay based on the transient expression of a GFP -PR fusion protein. Treatment with protease inhibitors results in a dose-dependent accumulation of the GFP, which can be used to calculate the drug IC 50 . In the present study, we extended, improved and validated with clinical samples this phenotypic assay. We modified the cloning vector to facilitate the introduction of HIV-1 proteases from HIV-1 isolates of infected subjects. To do so, we replaced the original HIV-1 protease from the plasmid containing the GFP-PR with a polylinker before cloning 46 clinical isolates to further evaluate the method. We also improved detection of the GFP reporter gene using the molecular mechanism described above. When comparisons between values obtained by our assay and those of classic phenotyping assays were performed, the results showed that our method had a high degree of reliability and was comparable to other, widely used assays based on both genotypic and phenotypic data. Excellent correlations coefficients were observed in all cases. Therefore, we were able to evaluate and validate the predictive potential of our noninfectious method.
We propose a new hypothesis of phenotyping based on a molecular approach. This hypothesis was based on the ability of HIV-1 protease to cleave cellular translation factors such as eIF4GI and PABP ( Figure S2 , available as Supplementary data at JAC Online). Despite its own function within the viral cycle, HIV-1 protease has been related to the processing of non-viral proteins, such as cytoskeleton proteins, vimentin, desmin, troponin C, Alzheimer myeloid precursor, pro-interleukin 1B, eukaryotic initiation factor eIF4GI and PABP. 12,20 -24 To confirm our hypothesis, we performed cell viability assays and compared GFP mRNA expression results with western blot analysis. The results showed that down-expression of the GFP reporter gene when the protease was fully acting on the system was not related to a process compatible with necrosis or apoptosis; thus, ruling out the possibility that HIV-1 protease is inducing cell killing within the system. In addition, transcription of the GFP reporter gene was independent of the protease resistance mutations contained within the plasmids and the drug concentration used, suggesting that the molecular mechanism of our phenotyping method was independent of cellular transcription machinery. However, western blot analysis did show that the pattern of resistance mutations within HIV-1 protease and the concentration of the protease inhibitor were able to modulate the translation of GFP, indicating that our phenotyping system most likely depends on the ability of HIV-1 protease to cleave cellular translation factors. One limitation of this assay is that the cloning vector only incorporates the HIV-1 protease and its flanking cleavage sites, and therefore does not take into account the potential effect of mutations in other viral domains, such as the Gag cleavage sites, which might be important in the evaluation of phenotypic susceptibility to protease inhibitors.
Finally, this phenotypic method is highly sensitive to protease inhibitors; IC 50 values obtained for wild-type protease in the present study are comparable to previously reported phenotypic data. In addition, the system is safe and does not involve the generation of replication-competent viruses. This assay can optimize decision-making when establishing salvage treatments with protease inhibitors.
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